"It is probably obvious to others but not me as to why RVX does not let people know the status as the trial moves toward it's end goal of 250 MACE events."

Yes, I agree Toinv. Management knows the current number of adjudicated 3-point MACE events and has the power to communicate that status more clearly. For example, Amarin issues three news releases for their ongoing REDUCE-IT CVOT trial at 80%, 90% and near 100% of planned MACE events. There is no requirement for Resverlogix to communicate this, but it would go a long way towards bolstering confidence and reducing uncertainty.

As I pointed out before, the mid-March news release and mid-March MD&A were the last official communications from the company stating that there was still a plan to execute an SSRA at 75% of total events (188 events). Since then, the only other mention of the 188 event SSRA that I was able to find was in the April 12, 2018 Zacks analyst report that reiterated this SSRA plan.

This April 12, 2018 Zacks report is the most recent of the four analyst reports that I have seen. Stonegate was in mid-March 2018. Van Leeuwenhoeck Institute was in January 2018. The initial Beacon report was in December 2017. We should be seeing updated analyst reports soon. However, these analyst updates are likely contigent upon Resverlogix actually communicating detailed and explicit company updates!

Based upon the past history of MD&A filings on SEDAR, the next one isnt' due until late July. I expect that to be the longest that we will have to wait for some explicit updates from management. Hopefully sooner. As Kelsee pointed out (thanks Kelsee!), we are ripe for the 7th DSMB report that could very well include the SSRA results.  

Tick tock.

BearDownAZ